Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 70Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Rectal Neoplasms 13Colonic Neoplasms 13Neoplasm Metastasis 12Esophageal Neoplasms 11Neoplasms 9Gallbladder Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Bile Duct Neoplasms 7Liver Neoplasms 6Adenocarcinoma Of Esophagus 5Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Gastrointestinal Neoplasms 3Esthesioneuroblastoma, Olfactory 3Esophageal Squamous Cell Carcinoma 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Pancreatic Intraductal Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Carcinoma, Renal Cell 2Biliary Tract Neoplasms 2Anus Neoplasms 2Adenomatous Polyposis Coli 2

Interventions

pembrolizumab 12Nivolumab 6Cyclophosphamide 6fludarabine 5Ipilimumab 4amatuximab 3Cisplatin 3tislelizumab 2spartalizumab 2fludarabine phosphate 2budigalimab 2belinostat 2Plicamycin 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorouracil 2Cytoreduction Surgical Procedures 2venetoclax 1tocilizumab 1talazoparib 1sotorasib 1rovalpituzumab tesirine 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1irinotecan sucrosofate 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Erlotinib Hydrochloride × Gastrointestinal × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡